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obJeCtive Symptomatic chronic subdural hematoma (CSDH) will become an increasingly common presentation in 
neurosurgical practice as the population ages, but quality evidence is still lacking to guide the optimal management for 
these patients. The British Neurosurgical Trainee Research Collaborative (BNTRC) was established by neurosurgical 
trainees in 2012 to improve research by combining the efforts of trainees in each of the United Kingdom (UK) and Ire-
land’s neurosurgical units (NSUs). The authors present the first study by the BNTRC that describes current management 
and outcomes for patients with CSDH throughout the UK and Ireland. This provides a resource both for current clinical 
practice and future clinical research on CSDH.
MethoDs Data on management and outcomes for patients with CSDH referred to UK and Ireland NSUs were col-
lected prospectively over an 8-month period and audited against criteria predefined from the literature: NSU mortality 
< 5%, NSU morbidity < 10%, symptomatic recurrence within 60 days requiring repeat surgery < 20%, and unfavorable 
functional status (modified Rankin Scale score of 4–6) at NSU discharge < 30%.
resUlts Data from 1205 patients in 26 NSUs were collected. Bur-hole craniostomy was the most common procedure 
(89%), and symptomatic recurrence requiring repeat surgery within 60 days was observed in 9% of patients. Criteria on 
mortality (2%), rate of recurrence (9%), and unfavorable functional outcome (22%) were met, but morbidity was greater 
than expected (14%). Multivariate analysis demonstrated that failure to insert a drain intraoperatively independently pre-
dicted recurrence and unfavorable functional outcome (p = 0.011 and p = 0.048, respectively). Increasing patient age (p 
< 0.00001), postoperative bed rest (p = 0.019), and use of a single bur hole (p = 0.020) independently predicted unfavor-
able functional outcomes, but prescription of high-flow oxygen or preoperative use of antiplatelet medications did not.
ConClUsions This is the largest prospective CSDH study and helps establish national standards. It has confirmed in 
a real-world setting the effectiveness of placing a subdural drain. This study identified a number of modifiable prognostic 
factors but questions the necessity of some common aspects of CSDH management, such as enforced postoperative 
bed rest. Future studies should seek to establish how practitioners can optimize perioperative care of patients with 
CSDH to reduce morbidity as well as minimize CSDH recurrence. The BNTRC is unique worldwide, conducting multi-
center trainee-led research and audits. This study demonstrates that collaborative research networks are powerful tools 
to interrogate clinical research questions.
https://thejns.org/doi/abs/10.3171/2016.8.JNS16134
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ChroniC subdural hematoma (CSDH) is a collec-tion of liquefied blood between the dura mater and the arachnoid layer of the brain. The incidence 
is 8.2/100,000/year after 70 years of age.2 With an age-
ing population, a rise in CSDH prevalence is anticipated. 
Spontaneous resolution can occur, but surgical evacuation 
is indicated in patients who deteriorate or do not improve. 
However, there is little Level I evidence describing opti-
mal surgical and perioperative management strategies.
The 3 most common surgical techniques to treat CSDH 
are twist-drill craniostomy (TDC), bur-hole craniostomy 
(BHC), and craniotomy. Although all 3 techniques have 
approximately the same mortality rate (2%–4%), crani-
otomy has significantly higher morbidity, and TDC has a 
higher rate of recurrence, suggesting that BHC is the pre-
ferred technique.25 In contrast, a more recent meta-analy-
sis concluded that TDC should be the first-line treatment, 
with craniotomy reserved for symptomatic recurrence.8
Other aspects of perioperative and postoperative man-
agement may also influence outcome. A randomized 
controlled trial (RCT) demonstrated that subdural drains 
left in situ after BHC reduced CSDH recurrence requir-
ing redrainage (9.3% vs 24.0% recurrence with vs without 
drain).21 The benefit of drains was confirmed in a recent 
meta-analysis.3 However, conflicting evidence for other 
aspects of CSDH management leads to considerable varia-
tion in practice. For example, the optimal number of bur 
holes (1 vs 2) or the benefit of using intraoperative irriga-
tion is uncertain.12,19,23 Postoperatively there is contradic-
tory advice about the relative risks and benefits of bed rest 
versus early mobilization.1,15,17 The benefit of corticoste-
roids as either a primary treatment or an adjunct to sur-
gery remains unclear.6,26 Opinions also vary regarding the 
need to administer agents to mitigate the biological effects 
of antiplatelet agents (e.g., platelet transfusion for aspirin). 
Observational studies suggest that antiplatelet and antico-
agulant use preoperatively is associated with higher rates 
of CSDH recurrence.4,9,22 Conversely, a retrospective study 
of 58 patients suggested that early surgery for those tak-
ing antiplatelets without drug cessation or platelet infusion 
may be safe.18
Patients with CSDH would benefit from a stronger evi-
dence base for the management of this condition. The pres-
ent study aims to present the clinical, management, and 
outcome characteristics for patients with CSDH across the 
United Kingdom (UK) and Ireland. From these data we 
aimed to identify variables independently associated with 
symptomatic CSDH recurrence and unfavorable outcomes 
that could be interrogated in future studies. This was the 
first study to be conducted by the British Neurosurgical 
Trainee Research Collaborative (BNTRC).
Methods
We conducted a nationwide, multicenter, prospective 
cohort study to describe the clinical characteristics of 
patients with CSDH, to assess the variation in operative 
and perioperative strategies, and to ascertain short-term 
outcomes evaluated against best-practice criteria as de-
termined from a review of the published literature. The 
Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) checklist was used in the prepa-
ration of this manuscript.24
Participants and study settings
Study participants were identified and enrolled at 26 
of the 33 UK and Ireland neurosurgical units (NSUs) 
between May 2013 and January 2014. Eligibility criteria 
were age > 16 years, presentation with a primary or recur-
rent CSDH confirmed on cranial imaging, and referral to 
a participating NSU. A CSDH was defined radiologically 
as a predominantly hypodense, isodense, or mixed-den-
sity subdural collection. Patients with other pathologies 
identified at operation or during subsequent management 
were excluded (e.g., vascular malformations, subdural 
empyema). The study protocol was approved by the Aca-
demic Committee of the Society of British Neurological 
Surgeons (SBNS) and has been published previously.7 The 
study was supported by the SBNS and formed part of the 
Neurosurgical National Audit Program.
outcome Measures and audit standards
Audit standards were determined from the literature, as 
described previously:7 NSU mortality < 5%, NSU morbid-
ity < 10%, symptomatic recurrence within 60 days requir-
ing repeat surgery < 20%, and unfavorable functional sta-
tus (modified Rankin Scale [mRS] score of 4–6) at NSU 
discharge < 30%.
Data Collection
The BNTRC is a network of neurosurgical trainees and 
supervising consultants in each NSU in the UK and Ire-
land. Local trainee investigators identified patients at the 
time of admission to the NSU from on-call referral data-
bases or operating theater logbooks. Patient demographic 
data, baseline characteristics including medical comorbid-
ities and relevant medication history, and details of pre-, 
intra-, and postoperative management were collected. A 
minimum data set including baseline characteristics and 
proposed management was collected for patients referred 
to but not transferred into the NSU. Reoperation within 
60 days of index admission was identified and recorded. 
The mRS score at discharge from the NSU, morbidity and 
mortality in the NSU, destination at discharge from the 
NSU, and length of stay in the NSU were also recorded.
Data were submitted to a secure online database main-
tained by the Outcome Registry Intervention and Opera-
tion Network (ORION) at the University of Cambridge. 
The ORION database complies with Department of 
Health Information Governance policies and with stan-
dards for secure processing of patient health care data laid 
out in the Information Governance Toolkit of the Health 
and Social Care Information Centre. Each NSU was the 
data controller for its own data. Local governance approv-
als were in place in each participating NSU.
Data analysis
Anonymized data were collated and checked for errors 
prior to analysis. Patients with missing data sets were ex-
cluded if the missing data were relevant to that particular 
analysis. Data were analyzed according to the predefined 
observational cohort study of chronic subdural hematoma
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audit standards, using 1-sample tests. Multivariable logis-
tic regression models were used to assess the impact of 
variables on outcome, and odds ratios are reported. Data 
were analyzed using IBM SPSS Statistics software, ver-
sion 21.
results
Demographic Data
Data were collected for 1205 patients with CSDH re-
ferred to 26 NSUs; recruitment per unit ranged from 4 
to 175 patients (mean 46 patients). Of 1205 patients re-
ferred, 823 (68.3%) were accepted for NSU admission. In 
the remaining 382 patients, CSDH was managed at their 
referring hospital; 24 of these patients were subsequently 
transferred to the NSU, but have been excluded from the 
outcome analysis because of incomplete data. The most 
common reason for not being transferred was that the 
subdural collection was considered small and insufficient 
to explain a patient’s symptoms, or that the patient was 
asymptomatic (Table 1).
baseline Clinical Characteristics of transferred Patients
The median age of patients who were admitted was 77 
years (range 20–99 years). Sixty-eight percent were male, 
and 62% (514/823) had a documented history of head in-
jury in the preceding 3 months. The demographic and 
baseline characteristics of patients are listed in Table 2.
Cognitive impairment was the most frequent present-
ing symptom of transferred patients (58%), followed by 
hemiparesis (41%) and headache (41%) (Table 2). The ma-
jority of patients had a Glasgow Coma Scale (GCS) score 
of 13–15 (88%), which was not significantly different from 
nontransferred patients (89%). Patients’ functional status 
on admission was determined using the mRS, and the me-
dian score was 3.
Management of CsDh in Patients transferred to an nsU
Steroid Use
Twenty-six patients (3%) received a course of dexa-
methasone. Sixteen (2%) received the drug as the pri-
mary treatment modality for a median of 6.5 days (range 
3–21 days), with a median dose of 4 mg per day (range 
4–16 mg). In 10 patients (1%) steroids were administered 
as adjuvant treatment perioperatively for a median of 6 
days (range 1–40 days), with a median dose of 8 mg per 
day (range 4–12 mg). Of the 382 patients who were not 
transferred, steroid therapy was recommended in 39 cases 
(10%).
Perioperative Clotting
Of the patients who were transferred, in 356/823 (43%) 
anticoagulant or antiplatelet medication was prescribed at 
the time of referral: 171 received aspirin (21%), 160 war-
farin (19%), 36 clopidogrel (4%), 6 dipyridamole (1%), 
and 12 got other medications not listed (1%). Aspirin was 
discontinued a median of 3 days prior to surgery (range 
0–44 days). Of the patients taking aspirin, 49/171 (28.7%) 
received a transfusion of platelets preoperatively. For pa-
tients taking warfarin (n = 160), the most common reversal 
strategies were vitamin K + clotting factors (82), vitamin 
table 1. reasons why 382 patients were not transferred to 
the nsU
Reason
No. of 
Patients (%)
Small collection & not sufficient to explain symptoms 152 (40)
Small collection, patient believed to be asymptomatic 119 (31)
Deemed not in best interest due to comorbidities 62 (16)
Receiving antiplatelet or anticoagulation meds—to be 
admitted for elective drainage
31 (8)
Deemed futile due to poor status 18 (5)
Meds = medications.
table 2. Demographic data and baseline characteristics for 823 
patients who were transferred to the nsU
Characteristic No. of Patients (%)
Premorbid mobility
 Independent 585 (71) 
 Walking stick 151 (18)
 Zimmer frame 75 (9) 
 Wheelchair 8 (1)
 Bed bound 4 (<1)
Premorbid residence
 Independent 637 (77) 
 Caregiver 128 (16)
 Residential home 37 (4) 
 Nursing home 21 (3)
Reported medical history
 Ischemic heart disease 208 (25)
 Arrhythmia 172 (21)
 Diabetes 133 (16)
 Cerebrovascular disease 132 (16)
 Dementia 89 (11)
 Malignancy 70 (9)
 Chronic obstructive pulmonary disease 49 (6)
 Epilepsy 35 (4)
 Metallic valve 18 (2)
 Shunt 7 (1)
Presenting complaint*
 Cognitive impairment 480 (58)
 Hemiparesis 336 (41)
 Headache 336 (41)
 Gait disturbance 264 (32)
 Dysphasia 118 (14)
 Incontinence 39 (5)
 Seizure 30 (4)
 Facial droop 28 (3)
 No documented symptoms 33 (4)
* Individual patients often had multiple medical problems and presenting 
complaints.
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K alone (28), or clotting factors alone (20). Reversal treat-
ment was not reported in 22 patients (14%).
Surgical Treatment
Surgical procedures were performed in 787 of 823 pa-
tients (96%): 76% by registrars, 21% by senior house of-
ficers, and 3% by consultants. Most operations were per-
formed after induction of general anesthesia (93%).
Bur-hole craniostomy was the most frequent procedure 
(700/787 [89%]), followed by craniotomy (72/787 [9%]), 
and TDC in just 1 case (< 1%); the remaining 14 patients 
had a craniectomy, or BHC and craniotomy on different 
sides. Unilateral BHC was most commonly performed 
using 2 bur holes (89%); 10% had a single bur hole. Bur 
holes were irrigated intraoperatively to remove the sub-
dural collection in 99% of cases, and a drain was used in 
85% of cases; the drains were most often sited subdurally 
(92%) rather than subgaleally. Drains were left in situ for 
48 hours (68%) or 24 hours (28%).
Postoperative Management
Postoperative bed rest was prescribed in 61% of patients 
after BHC (median 12–24 hours). Only 10% of patients 
undergoing BHC received prescribed high-flow oxygen 
postoperatively. Postoperative cranial imaging was per-
formed in 380 (48%) patients after surgery; the investiga-
tion was described as routine in 58%.
Patient outcomes
Outcomes were determined against the previously de-
scribed criteria.
Mortality 
The audit standard for all causes of mortality in the 
NSU was < 5%. The mortality and morbidity data were 
reported for 798/823 transferred patients. Eighteen of 798 
patients (2%) died during the study. Causes of death in-
cluded pneumonia (10), other sepsis (2), and stroke (3).
Morbidity 
The audit standard for all causes of morbidity in the 
NSU was < 10%. The NSU morbidity rate was 14% 
(111/798), mainly from respiratory tract infection (8%) 
(Table 3).
symptomatic recurrence requiring surgery 
The audit standard for symptomatic recurrence requir-
ing surgery was a rate of < 20%. Follow-up data were 
available for all 787 patients who underwent surgery. Re-
currence occurred within 60 days of primary surgery in 
73 patients (9%). The median duration of time to reopera-
tion was 12 days (range 0–57 days). There was no signifi-
cant difference in recurrence between patients who had 
BHC or craniotomy (p = 0.831).
We determined variables associated with symptomatic 
recurrence in the 684 patients who underwent de novo 
BHC for whom data were available, using logistic regres-
sion (Table 4). Sixteen patients for whom the BHC was for 
a CSDH recurrence were excluded from analysis.
Drain insertion after BHC (p = 0.011, OR 0.414) and 
a higher preoperative GCS score (p = 0.008, OR 0.859) 
were predictive of reduced recurrence after controlling for 
the variables shown in Table 4. These same variables re-
mained predictive of recurrence when all 772 BHC and 
craniotomy patients were considered together (p = 0.0003, 
OR 0.347 and p = 0.002, OR 0.855, respectively).
We dichotomized the 684 patients treated with BHC ac-
cording to whether they had unilateral or bilateral CSDH. 
One hundred fifty-seven of 202 patients in whom bilat-
eral CSDH was documented underwent bilateral BHC. In 
patients with unilateral BHC, a higher preoperative GCS 
table 3. Perioperative morbidity during nsU admission
Postop Morbidity No. of Episodes (% of patients)
Pneumonia 60 (8)
Neurological deficit 39 (5)
Seizure 19 (2)
Arrhythmia 12 (2)
Stroke 9 (1)
Surgical site infection 8 (1)
Myocardial infarction 4 (<1)
Venous thromboembolism 4 (<1)
Some patients had > 1 episode of morbidity recorded (155 episodes experi-
enced by 111 patients).
TABLE 4. Factors influencing symptomatic recollection of CSDH requiring repeat surgery within 60 days after de novo BHC
Variable No Recurrence, n = 626 Recurrence, n = 58 OR p Value
Median age in yrs, interquartile range 77, 67–84 80, 70–87 1.011 0.299
Preop GCS score, range 14, 14–15 14, 11.75–15 0.859 0.008
On antiplatelet meds* 24% 19% 0.673 0.266
Mixed-density clot 49% 57% 1.351 0.293
>1 bur hole 92% 90% 0.902 0.833
Bilat op 24% 26% 1.167 0.635
Drain inserted 86% 74% 0.414 0.011
Bed rest 61% 57% 0.853 0.586
High-flow O2 9% 9% 0.887 0.811
Calculated with logistic regression. The ORs are for CSDH recollection. Three patients were not included in logistic regression because their age was missing.
* For the majority of patients in whom anticoagulants were prescribed, the international normalized ratio (INR) was corrected prior to surgery so that INR was not 
considered as a variable in this logistic regression analysis.
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score (p = 0.006, OR 0.839) and drain insertion after BHC 
(p = 0.004, OR 0.317) were still predictive of reduced re-
currence. In the group that underwent bilateral BHC, none 
of the variables reached statistical significance (Supple-
mentary Table 1). Bilateral BHC was not an independent 
risk factor for recurrence (p = 0.867).
There was no significant difference in recurrence rates 
between patients having 1 bur hole (10%) or multiple bur 
holes (8%) for unilateral CSDH (p = 0.875) when control-
ling for the other variables. Antiplatelet medication use 
preoperatively, the administration of high-flow oxygen in 
the postoperative period, and bed rest did not independent-
ly affect recurrence significantly (p = 0.266, p = 0.811, and 
p = 0.586, respectively), even when the BHC cohort was di-
vided into unilateral and bilateral CSDH groups (Table 4, 
Supplementary Tables 1 and 2). The preoperative appear-
ance on CT imaging of a mixed-density subdural collec-
tion, rather than a homogeneously isodense or hypodense 
clot, did not predict recurrence (p = 0.293) (Table 4).
Functional outcome 
The audit standard for functional outcome was an unfa-
vorable mRS score (4–6) at NSU discharge of < 30%. The 
mRS score data were available for 798 patients at the point 
of discharge. An unfavorable mRS score occurred in 176 
patients (22%). The median mRS score was 2, compared 
with 3 preoperatively (Fig. 1). Factors predicting an unfa-
vorable mRS score were determined in the 684 patients 
who had de novo BHC by using logistic regression; 148 
of these patients had an unfavorable mRS score (Table 5).
In the BHC group a favorable preoperative mRS score 
(≤ 3) was independently predictive of a favorable mRS 
score at discharge (p < 0.00001, OR 2.13), as was drain 
insertion (p = 0.048), good preoperative GCS score (p 
= 0.01), and lower age (p < 0.00001); the median age of 
patients with a favorable mRS score was 76 years (range 
65–83 years), compared with 84 years (range 76–88 years) 
for those with an unfavorable mRS score. Prescribed post-
operative bed rest predicted a poor outcome (p = 0.019). 
Interestingly, although the number of bur holes for BHC 
did not predict recurrence, the use of multiple bur holes 
did predict a favorable functional outcome (p = 0.020). 
Preoperative midline shift did not significantly correlate 
with functional outcome (p = 0.857).
The same factors remained significant predictors of 
Fig. 1. Bar graph showing a comparison of the proportion of all patients with a given mRS score in the pre- and postoperative 
patient cohorts. The graph demonstrates the shift to better functional status on discharge compared with status on admission to 
the NSU. 
TABLE 5. Factors influencing functional outcome at NSU discharge after de novo BHC
Variable Favorable mRS Score (0–3), n = 518 Unfavorable mRS Score (4–6), n = 148 OR p Value
Median age in yrs, inter- 
 quartile range
76, 65–83 84, 76–88 1.074 <0.00001
Initial mRS score, range 3, 2–4 4, 3.25–4 2.131 <0.00001
Preop GCS score, range 14, 14–15 14, 12–14 0.871 0.011
On antiplatelet meds 20% 33% 1.326 0.236
Mixed-density clot 49% 52% 0.805 0.329
>1 bur hole 93% 86% 0.412 0.020
Bilat op 25% 23% 1.176 0.530
Drain inserted 85% 83% 0.497 0.048
Bed rest 58% 67% 1.747 0.019
High-flow O2 9% 9% 0.732 0.408
Calculated with logistic regression. The ORs are for unfavorable functional outcome. Of 684 patients, in 18 the outcome was not recorded; 3 more were not included in 
logistic regression because their age was not recorded.
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poor outcome when the patients treated with BHC were 
considered along with those treated with craniotomy. 
When patients with unilateral or bilateral CSDH were ex-
amined separately, age and initial mRS score remained 
significant in both groups (p < 0.0001 and p = 0.0018, re-
spectively; see Supplementary Tables 3 and 4). In the uni-
lateral BHC–only group, bed rest (p = 0.001, OR 2.637) 
and drain insertion (p = 0.002, OR 0.320) increased in 
significance; having multiple bur holes was unchanged (p 
= 0.030, OR 0.407); and preoperative GCS score became 
almost nonsignificant (p = 0.054, OR 0.887).
Length of Stay and Discharge Destination
The median length of NSU stay was 7 days (range 
1–179 days); there was no statistical difference between 
patients treated with BHC and craniotomy. At NSU dis-
charge, 47% of patients (358) were transferred to a local 
hospital for ongoing care, and 49%—one-sixth of whom 
required caregivers—were discharged home.
Discussion
This was the BNTRC’s first study and represents the 
largest prospective, observational, multicenter study of 
CSDH management, NSU outcomes, and 60-day recur-
rence rates. The BNTRC was established by neurosurgical 
trainees in 2012 to improve research by combining the ef-
forts of trainees in each of the UK and Ireland’s NSUs.14 
The collaborative group provides a semiformal structure 
to support individuals; a steering group devises the project 
protocol and invites trainees to join the study as collabo-
rators. Individual trainees in each NSU volunteer as data 
collectors. Both authorship and collaborator status on pub-
lications is defined in advance. Upon project completion 
the data become available to all collaborating members to 
permit further analysis.
This study provides valuable insights into current man-
agement practices for patients with CSDH. It will inform 
contemporary practice. It validates in a real-world set-
ting the 2009 RCT that demonstrated the effectiveness of 
subdural drain insertion.21 Other key observations should 
be validated in prospective trials. The study defines the 
current standard of care for patients with symptomatic 
CSDHs as bur-hole drainage with insertion of a subdural 
drain for 24–48 hours. There was no clear preference for 
prescribed bed rest or high-flow oxygen in the postopera-
tive period; bed rest was actually associated with unfavor-
able functional outcome.
Current practice exceeded predefined audit standards 
for functional outcome at discharge, in-NSU mortality, 
and 60-day postoperative symptomatic CSDH recurrence. 
However, the 14% incidence of postoperative morbidity 
was greater than the audit standard of < 10%. This may 
reflect better data collection in our prospective study com-
pared with existing retrospective studies. Interestingly, 
the previously largest series (retrospective) of surgically 
treated cases of CSDH reported 19.6% morbidity.10 There 
is nevertheless an opportunity to optimize care for CSDH 
patients, many of whom are elderly and have multiple co-
morbidities. There may be parallels to achieving this in 
the same way that changes to perioperative care of patients 
with femural neck fractures reduced mortality in that vul-
nerable population.13 The BNTRC is therefore collaborat-
ing on a prospective study to examine how to optimize 
perioperative factors in patients with CSDH to improve 
the management of their condition.
The decision to proceed with revision surgery was at 
the discretion of the patient’s consultant neurosurgeon, 
based on clinical symptoms, correlated with imaging. The 
9% rate of symptomatic recurrence we observed at 60 days 
may have underestimated the true rate if there were late re-
currences, but previous studies have suggested that recur-
rence is most likely within this time frame.16 The median 
time to recurrence in the present study agrees with that re-
ported previously.4 Our study demonstrated that only 48% 
of surgically treated patients underwent postoperative im-
aging, so there may have been incidents of recurrence that 
did not reach clinical significance but would have been de-
tected radiologically. Because the need for redo surgery is 
based on symptomatic recurrence, radiological recurrence 
alone is of less importance.
We observed that the number of bur holes was not an 
independent risk factor for CSDH recurrence after BHC, 
but single bur holes were associated with worse functional 
outcomes at discharge. Preoperative mRS score was not 
predictive of the number of bur holes used in BHC, and the 
reason for the worse functional outcomes is not clear. Pre-
vious retrospective studies have suggested that a single bur 
hole is as effective as 2 in selected cases.11,12 Future studies 
should interrogate this further. A single bur hole may be 
preferred if associated with reduced operative length and 
in turn lower postoperative morbidity, but this has yet to 
be demonstrated.
Multiple bur holes may traditionally be preferred where 
there is a mixed-density subdural collection (mixed be-
tween hyperdense and isodense or hypodense material). 
This is because the hyperdense material represents more 
acute blood that is thicker than isodense or hypodense 
blood and does not discharge as easily from a single bur 
hole. However, our study identified that the radiological 
appearance of the subdural collection was not predictive 
of symptomatic recurrence. This may be because the goal 
of surgery is to reduce the mass effect from the CSDH, 
not necessarily to remove the hematoma altogether; the 
residual subdural collection can resolve spontaneously. A 
single bur hole may be adequate to achieve this, and, in-
terestingly, we observed no correlation between subdural 
density and the number of bur holes used for BHC.
Evidence for the benefit of corticosteroids in CSDH 
management remains scarce. Our study documented ste-
roid use in only a small proportion of patients. The effect 
of dexamethasone on reduction of the reoperation rate for 
CSDH is the focus of several ongoing studies, including an 
RCT comparing dexamethasone to placebo after BHC, a 
study supported by the BNTRC (dexcsdh.org).
Anticoagulant and antiplatelet use have been impli-
cated in both the development and recurrence of CSDH.5 
In our study, 43% of the patients transferred to an NSU 
for treatment were taking an antiplatelet or anticoagulant 
medication. Strategies for the preoperative optimization of 
platelet function and coagulation in these patients varied 
greatly, but the preoperative prescription of antiplatelet 
agents was not an independent risk factor for recurrence. 
The impact of anticoagulant agents was not examined, be-
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cause all patients receiving these agents had their inter-
national normalized ratio (INR) corrected preoperatively. 
Although the use of antiplatelet agents was not observed to 
be associated with recurrence, the heterogeneity in timing 
of the discontinuation of medication and of reversal strate-
gies suggests that this observation should be interpreted 
cautiously. Nevertheless, it remains feasible that some pa-
tients may not need to discontinue their medication for the 
traditional 7 days before bur-hole surgery. This could be 
important, because delay in recommencing these thera-
pies is associated with thromboembolic risk, and the delay 
of surgery while managing anticoagulant and antiplatelet 
therapies may also be associated with increased morbidity.
Although our observations are based on data from the 
UK and Ireland, the results will be of interest internation-
ally because CSDH is common worldwide. There will 
undoubtedly be variations between countries in the pref-
erence for some aspects of CSDH management that were 
not well represented in UK practice, such as prescription 
of steroids or use of TDC. The design of prospective stud-
ies to develop an evidence base for CSDH management 
should include all these factors.
There are some limitations to our study. For example, 
we captured data from patients whose CSDH was man-
aged in NSUs, so we do not know the natural history of 
patients with CSDH that was managed in hospitals without 
NSUs. We examined relatively short-term outcome mea-
sures, and longer-term outcome measures such as 6-month 
functional status and mortality rate would be valuable. Our 
patient cohort was skewed to management with BHC, so 
we could not make a meaningful analysis of variables pre-
dicting outcome in the craniotomy subgroup. In addition, 
our study demonstrated that surgical drainage of CSDH 
is performed almost exclusively by trainee neurosurgeons 
and senior house officers. This is clearly standard practice 
in the UK, and a previous study has found no association 
between seniority of the surgeon and postoperative recur-
rence of CSDH.20 It should also be noted that it is our expe-
rience that a consultant neurosurgeon is always the person 
to make a decision to proceed to surgery and is available 
if needed. The question may nevertheless be raised as to 
whether patient outcomes would be different if consultant 
surgeons were the primary surgeon. This is an important 
question for future study.
Conclusions
We have defined the preferred strategy for treating 
symptomatic CSDH as bur-hole drainage with a postoper-
ative closed drainage system. We have observed that many 
variations in practice do not significantly impact outcome. 
Further research is required to examine these relationships 
in more detail and to determine whether standardization 
of management can improve patient outcomes.
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